DelveInsight’s, “Epidermolysis Bullosa Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 22+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epidermolysis Bullosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore clinical-stage developments and strategic collaborations transforming the industry! @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight

Key Takeaways from the Epidermolysis Bullosa Pipeline Report

• On May 20, 2026, Xinnate AB initiated a Phase 2 study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, a pair of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.
• DelveInsight’s Epidermolysis Bullosa pipeline report depicts a robust space with 18+ active players working to develop 22+ pipeline therapies for Epidermolysis Bullosa treatment.
• The leading Epidermolysis Bullosa Companies such as BioMendics, InMed Pharmaceuticals, Castle Creek Biosciences, Eloxx Pharmaceuticals, Aegle Therapeutics, Xinnate, TWi Biotechnology, Inc., and Tay Therapeutics and others.
• Promising Epidermolysis Bullosa Pipeline Therapies such as diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.

Learn how leading Epidermolysis Bullosa Companies are positioning themselves for success in the evolving pharmaceutical market @ Epidermolysis Bullosa Clinical Trials Assessment

Epidermolysis Bullosa Overview

Epidermolysis Bullosa refers to a group of rare inherited skin disorders characterized by extreme skin fragility, leading to recurrent blistering, erosions, and ulcers even after minor mechanical trauma. These conditions arise from genetic defects affecting proteins at the dermo-epidermal junction, resulting in impaired skin integrity. EB presents with a wide spectrum of severity, with some forms associated with chronic infections, scarring, deformities, and an elevated risk of aggressive skin cancers. In addition to cutaneous symptoms, patients may experience systemic complications that contribute to significant morbidity and early mortality.

Epidermolysis Bullosa Emerging Drugs

• BM-3103: BioMendics

TolaSure (BM-3103) is a topical therapeutic candidate being developed for the treatment of Epidermolysis Bullosa, a rare genetic skin disorder characterized by fragile skin and chronic blistering. The formulation is designed to enhance wound healing, reduce inflammation, and strengthen skin integrity at affected sites. By targeting local tissue repair mechanisms, it aims to accelerate re-epithelialization and minimize infection risk. TolaSure offers a non-invasive approach with the potential to improve quality of life in patients with this debilitating condition. BM-3103 is currently in Phase II stage of its development for the treatment of of Epidermolysis Bullosa.

• AGLE-102: Aegle Therapeutics

AGLE-102 is an investigational exosome-based therapy being developed for the treatment of Epidermolysis Bullosa. Derived from mesenchymal stem cells, it delivers bioactive molecules that promote tissue repair, reduce inflammation, and support skin regeneration. The therapy aims to accelerate wound closure and improve skin integrity in affected patients. AGLE-102 represents a novel, cell-free regenerative approach with potential to address the underlying pathology of this debilitating condition. It is currently being evaluated in a Phase I/II clinical trial for the treatment of Epidermolysis Bullosa.

Don’t miss this opportunity to stay informed—download now! @ Epidermolysis Bullosa Treatment Drugs

The Epidermolysis Bullosa Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.
• Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.

Epidermolysis Bullosa Companies

BioMendics, InMed Pharmaceuticals, Castle Creek Biosciences, Eloxx Pharmaceuticals, Aegle Therapeutics, Xinnate, TWi Biotechnology, Inc., and Tay Therapeutics and others

Epidermolysis bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Epidermolysis Bullosa Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download our report for a deep dive into the next generation of therapeutics! @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives

Scope of the Epidermolysis Bullosa Pipeline Report

• Coverage- Global
• Epidermolysis Bullosa Companies- BioMendics, InMed Pharmaceuticals, Castle Creek Biosciences, Eloxx Pharmaceuticals, Aegle Therapeutics, Xinnate, TWi Biotechnology, Inc., and Tay Therapeutics and others.
• Epidermolysis Bullosa Pipeline Therapies- diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.
• Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download now to stay at the forefront of pharmaceutical innovation!” @ Epidermolysis Bullosa Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Epidermolysis Bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Epidermolysis Bullosa– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. BM-3103: BioMendics
10. Early Stage Products (Phase I/II)
11. AGLE-102: Aegle Therapeutics
12. Preclinical and Discovery Stage Products
13. Inactive Products
14. Epidermolysis Bullosa Key Companies
15. Epidermolysis Bullosa Key Products
16. Epidermolysis Bullosa- Unmet Needs
17. Epidermolysis Bullosa- Market Drivers and Barriers
18. Epidermolysis Bullosa- Future Perspectives and Conclusion
19. Epidermolysis Bullosa Analyst Views
20. Epidermolysis Bullosa Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight